IP Library Granted Patent US 10,322,089
Granted Patent B2
US 10,322,089 · App. 13/799,883 · Granted Jun 18, 2019

Nanoparticles, nanoparticle delivery methods, and systems of delivery

Inventors: Tatsiana Lobovkina (Menlo Park, CA); Gunilla B. Jacobson (Taby, SE); Richard N. Zare (Stanford, CA); Evgenios Neofytou (San Carlos, CA); Ramin E. Beygui (Hillsborough, CA); Marie Russo (Stanford, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A61K9/51A61K9/5123A61K9/5192A61K47/543
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,322,089
App. No.
13/799,883
Granted
Jun 18, 2019
Kind
B2
Abstract

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to nanoparticles, compositions including nanoparticles, methods of making nanoparticles, and the like. In particular, embodiments of the present disclosure include nanoparticles and compositions for the sustained release (e.g., release at a predetermined rate to maintain a certain concentration for a certain period of time) of an agent, such as a small interfering RNA (siRNA) from the nanoparticle.

Claims (12)

1. A composition comprising:

a nanoparticle including a siRNA-cationic lipid conjugate, wherein the nanoparticle has a lipid monolayer enclosing a nanoparticle core, wherein the siRNA-cationic lipid conjugate is disposed within the nanoparticle core, wherein the lipid monolayer is selected from the group consisting of: lecithin, phosphatidylcholines, phosphatidic acid, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, cardiolipins, lipid-polyethyleneglycol conjugates, and a combination thereof,

wherein the nanoparticle core includes a liquid lipid, and

wherein the liquid lipid is a lipid extracted from adipose tissue.

2. The composition of claim 1 , wherein the liquid lipid is a lipid extracted from human adipose tissue.

3. The composition of claim 1 , wherein the nanoparticle has a diameter of about 150 to 800 nm.

4. The composition of claim 1 , wherein the nanoparticle core includes an agent selected from the group consisting of: a drug, an imaging agent, a nonionic surfactant, other types of lipids, and a combination thereof.

5. The composition of claim 1 , wherein the outside surface of the lipid monolayer includes an agent selected from the group consisting of: a drug, an imaging agent, a biocompatibility agent, a targeting agent, and a combination thereof.

6. A composition, comprising a nanoparticle including a siRNA-cationic lipid conjugate, wherein the nanoparticle has a lipid monolayer enclosing a nanoparticle core, wherein the siRNA-cationic lipid conjugate is disposed within the nanoparticle core,

wherein the nanoparticle core includes a liquid lipid, and

wherein the liquid lipid is a lipid extracted from adipose tissue,

wherein the cationic lipid is selected from the group consisting of: DOTAP, DC-Cholesterol, DODAP, DDAB, Ethyl PC, DOTMA, and a combination thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2013
From: LOBOVKINA, TATSIANA; JACOBSON, GUNILLA B.; ZARE, RICHARD N.; NEOFYTOU, EVGENIOS; BEYGUI, RAMIN E.; RUSSO, MARIE
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 030583/0388 →
CONFIRMATORY LICENSE Recorded May 13, 2013
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030406/0604 →
Continuity (2)
Provisional Application 61610524 · Mar 14, 2012
Related Publication 20130243848A1 · Sep 19, 2013